Tech Company Financing Transactions
Aerovance Funding Round
On 5/4/2006, Aerovance raised $60 million in Series C funding from Alta Partners, Clarus and Apax Partners.
Transaction Overview
Company Name
Announced On
5/4/2006
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series C
Investors
Alta Partners (Lead Investor) (Farah Champsi)
Clarus (Lead Investor) (Nicholas Galakatos)
Proceeds Purpose
With this financing, the company, which was spun out of Bayer Pharmaceutical Corp. in 2004, will have sufficient capital to advance two of its lead products through definitive clinical proof of concept.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
2929 7th St. 120
Berkeley, CA 94710
USA
Berkeley, CA 94710
USA
Phone
Website
Email Address
Overview
Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing biotherapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Perry
Chief Medical Officer
Tunde Otulana
Chief Technical Officer
Robert Kuhn
Executive Vice President
David Happel
Browse more venture capital transactions:
Prev: 5/4/2006: Innovectra venture capital transaction
Next: 5/5/2006: DotPhoto venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs